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BACKGROUND: Anti-cancer therapy is often a cause of premature ovarian insufficiency and infertility since the ovarian follicle reserve is
extremely sensitive to the effects of chemotherapy and radiotherapy. While oocyte, embryo and ovarian cortex cryopreservation can help
some women with cancer-induced infertility achieve pregnancy, the development of effective methods to protect ovarian function during
chemotherapy would be a significant advantage.
OBJECTIVE AND RATIONALE: This paper critically discusses the different damaging effects of the most common chemotherapeutic
compounds on the ovary, in particular, the ovarian follicles and the molecular pathways that lead to that damage. The mechanisms through
which fertility-protective agents might prevent chemotherapy drug-induced follicle loss are then reviewed.
SEARCH METHODS: Articles published in English were searched on PubMed up to March 2019 using the following terms: ovary, fertility
preservation, chemotherapy, follicle death, adjuvant therapy, cyclophosphamide, cisplatin, doxorubicin. Inclusion and exclusion criteria were
applied to the analysis of the protective agents.
OUTCOMES: Recent studies reveal how chemotherapeutic drugs can affect the different cellular components of the ovary, causing rapid
depletion of the ovarian follicular reserve. The threemost commonly used drugs, cyclophosphamide, cisplatin and doxorubicin, cause premature
ovarian insufficiency by inducing death and/or accelerated activation of primordial follicles and increased atresia of growing follicles. They
also cause an increase in damage to blood vessels and the stromal compartment and increment inflammation. In the past 20 years, many
compounds have been investigated as potential protective agents to counteract these adverse effects. The interactions of recently described
fertility-protective agents with these damage pathways are discussed.
WIDER IMPLICATIONS: Understanding the mechanisms underlying the action of chemotherapy compounds on the various components
of the ovary is essential for the development of efficient and targeted pharmacological therapies that could protect and prolong female fertility.
While there are increasing preclinical investigations of potential fertility preserving adjuvants, there remains a lack of approaches that are being
developed and tested clinically.
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Introduction
The effects of cancer and its treatment on female reproductive function
are increasingly well documented. Overall, compared to the general
population, women are 38% less likely to have a pregnancy after cancer
diagnosis and treatment, with all diagnostic groups of cancer being
associated with a reduction in the likelihood of subsequent pregnancies
(Anderson et al., 2018). Given this situation, there is now a pressing
need to develop methods to protect patients from the damaging
effects of treatment. This review therefore assesses the effectiveness
of potential treatments to protect the ovary against chemotherapy-
induced damage, with the work to date reported for only pre-clinical
studies, primarily animal models.
Over the last several decades, cervical cancer and breast cancer
have had the greatest impact on reducing the number of pregnancies
achieved, due to a combination of their high prevalence, the marked
effect of their associated treatments and patient age. Recent years have
seen improvements for these two particular malignancies and for other
cancers, such as Hodgkin lymphoma, although some diagnoses have
seen little, if any, change in their impact on subsequent chances of
pregnancy (Anderson et al., 2018).While radiotherapy and surgery can
have very significant adverse effects on female reproductive function,
this review focuses on the adverse effects of chemotherapy and on
possible approaches to reduce its impact. The adverse effects of
chemotherapy on ovarian function have long been recognised (Fig. 1A)
and there are increasingly detailed data documenting the effects of
different regimens on short-term markers of ovarian function, longer-
term fertility and risk of early menopause (Jayasinghe et al., 2018; van
Dorp et al., 2018). The impact of estrogen deficiency as a result of loss
of ovarian function on quality of life, bone function and cardiovascular
and neurological health are also critical aspects of the longer-term
effects of chemotherapeutic damage to the ovaries (European Society
of Human Reproduction and Embryology, 2015; Lobo, 2017). This has
led to the development of methods for female fertility preservation
(Anderson et al., 2015). The advent of oocyte vitrification was a key
advancement in the ability to successfully preserve postpubertal female
fertility (Argyle et al., 2016), while ovarian tissue cryopreservation
has had a growing evidence base with increasing documentation of
success rates; it is feasible prior to puberty and is now recognised as
an established rather than an experimental form of treatment in some
countries (Donnez and Dolmans, 2017).
Alongside the cryopreservation of gametes, a number of approaches
have also been explored with the aim of protecting ovarian follicles and
the oocytes they contain from chemotherapy-induced damage; these
are reviewed in this paper.
The use of GnRH analogues to protect ovarian function has been the
subject of a number of large randomised controlled trials, particularly
in breast cancer, and these results have been widely analysed and
discussed. It is now clear that this approach does reduce the prevalence
of premature ovarian insufficiency (POI) in women treated for breast
cancer (Lambertini et al., 2018) although it appears that relatively little
ovarian function, as reflected by anti-Müllerian hormone (AMH), may
be preserved by this approach (Leonard et al., 2017). The effectiveness
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of this approach in other cancers is not clear, with the largest trial
in women with lymphoma showing no apparent benefit (Demeestere
et al., 2016). Additionally, the benefits of this approach in terms of
subsequent pregnancy and the avoidance of the consequences of POI,
e.g., in bone health, remain to be clearly demonstrated in trials designed
with those outcomes as a primary objective. As this approach has been
extensively reviewed and is the subject of a number of meta-analyses
(including Del Mastro et al., 2014; Lambertini et al., 2018; Vitek et al.,
2014), it will not be discussed further here.
Methods
A thorough searchwas carried out for relevant articles in order to carry
out an extensive study on the ovarian damage induced by chemother-
apy and on new approaches to its protection. All authors contributed
to the search and to establish the inclusion and exclusion criteria. As
an analysis of published data, approval of an ethics committee is not
relevant.
The research was performed using PubMed and Medline as sources,
up to March 2019. The following keywords were used: chemotherapy,
cyclophosphamide (CPM), cisplatin (CIS), doxorubicin (DOX), fertility
preservation, adjuvant therapy, ovary, follicle death.
For the sections concerning the protective agents, the selection of
the papers was performed using PRISMA guidelines (Moher et al.,
2009), as described below and as reported in a PRISMA diagram
(Fig. 2). The research was performed using PubMed and Medline
as sources, up to March 2019. The following keywords were used:
chemotherapy, alkylating agents, anthracycline, female, ovary, adjuvant
therapy, fertoprotective therapy, fertility preservation, follicle death. All
relevant articles were carefully evaluated. Initially, titles and abstracts
were assessed to evaluate the eligibility of the studies. After this
selection, the authors proceeded with the complete reading of the
papers to identify those relevant for final inclusion. Reference lists of
these papers were checked to identify other studies that should be
included in this review. Only published articles, written in English and
peer-reviewed, were included. The search included both animal and
human studies. No restriction to any publishing year was applied, even
though the search showed that relevant papers were dated starting
from year 2000. Manuscripts were selected concerning protective
agents towards CPM, cisplatin and doxorubicin on the ovary, while
those concerning protective agents only against other chemotherapeu-
tic drugs and radiotherapy were excluded from the review. Manuscripts
describing no effect or adverse effects of the agents were included.
Reports only presented as conference proceedings were excluded.
Dynamics of the ovarian reserve
Underpinning the interpretation of the impact of chemotherapy on
ovarian function are the established findings that oogonia enter meiosis
during fetal life, and that the primordial follicle (PMF) pool is formed
early on, in utero in humans and around the time of birth in rodents.
These PMFs are located around the edge of the ovarian cortex, an area
with relatively little vasculature (Delgado-Rosas et al., 2009). There is a
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Figure 1 The damaging effects of chemotherapy drugs on the ovary and potential protectants against that damage.
(A) Chemotherapy drugs can damage the ovary by inducing prenatal loss of oogonia, direct loss of primordial follicles, accelerated activation of
primordial follicles, follicular atresia, stromal tissue damage, damage to the vasculature or inflammation. (B) Protectants examined to date have been
shown to protect against all ovarian damage pathways other than that to stromal tissue. Other protectants are designed to reduce drug delivery to the
ovary. PMF: primordial follicle; TRNS: transitional follicle.
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Figure 2 PRISMA flow diagram of literature search methodology for publications examining the effectiveness of potential
fertility protective agents. Search results, study screening, and study inclusion, following a review of the literature carried out using PRISMA
guidelines (Moher et al., 2009). Selected key words were searched in PubMed until March 2019, with 24 additional references identified through other
sources, resulting in examination of 1357 papers. After the analysis of all publications for the inclusion and exclusion criteria, 40 articles from the initial
search were used in this review.
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steady rate of activation of PMFs throughout the reproductive lifespan,
with its depletion resulting in the menopause. The biochemical path-
ways that regulate this activation of PMFs include growth factors acting
through pathways, including the PI3K/PTEN/Akt pathway and the
Hippo pathway (Ernst et al., 2017; Kawamura et al., 2013; Grosbois and
Demeestere, 2018). The Akt pathway is of particular importance here,
because it is modulated by both chemotherapy drugs and protectants,
as discussed below. This pathway acts via FOXO3a, which in rodents
is considered to be a key transcription factor in the maintenance of
resting follicles, with activation of a PMF marked by translocation of
FOXO3a from the nucleus to the cytoplasm (John et al., 2008; Chang
et al., 2015). Activity of this PI3K/PTEN/Akt pathway within oocytes
is a critical determinant of the size of the remaining PMF pool (Reddy
et al., 2008). Inhibitory factors are also important, including AMH
(Durlinger et al., 1999), but how these pathways and factors interact to
provide precise regulation of the activation of PMFs remains unclear.
Given the poor vasculature in the outer layer of the ovarian cortex
where the PMFs are located (Fig. 1A), it is possible that PMFs are
exposed to lower concentrations of chemotherapy drugs than the
well-vascularised later-stage follicles, as the drugs primarily reaching
PMFs via diffusion. The extent to which PMFs can be lost directly
through atresia or apoptosis is also unclear, although genetic studies
have documented a number of factors relating to apoptosis which
appear to have major roles in the regulation of the size of the PMF
pool. Some of these, such as the apoptotic regulator PUMA (Nguyen
et al., 2018; Myers et al., 2014), may be future targets for intervention in
the regulation of PMF loss, since they have particular roles in regulating
DNA damage-induced oocyte death once follicle growth has been
initiated, at least in the mouse (discussed more fully below), although
its role in humans is not yet known. The great majority of follicles will
become atretic at some stage during the follicular growth phase, and
the high proliferation rate of granulosa cells in growing follicles makes
them a sensitive target of many chemotherapy agents. Furthermore,
the need to maintain chromosomal and DNA integrity in the oocyte,
from PMF formation all the way through to subsequent ovulation and
thus potentially for decades, also renders the oocyte itself a key site
for the adverse effects of DNA-damaging chemotherapy agents.
Regulation of the rate at which PMFs undergo activation has an
added complexity arising from the interaction between PMFs and the
population of growing follicles. AMH produced by growing follicles is
thought to have an important inhibitory effect on the rate of PMF
activation (Durlinger et al., 1999), although evidence for this is much
clearer in the rodent than in the human or in other larger mono-
ovulatory mammalian species (Schmidt et al., 2005; Campbell et al.,
2012). Inhibitory interactions between neighbouring PMFs slowing
down the rate of activation have also been proposed (Da Silva-Buttkus
et al., 2009); since the spatial distributed of PMFs is in clusters, particu-
larly in the adult ovary (Gaytan et al., 2015), loss of some PMFs would
reduce the inhibitory influence on other PMFs within the cluster. As
such, loss of PMFs in chemotherapy-treated ovaries could be a result
of a direct pathway whereby PMFs become damaged and die and/or
due to an indirect pathway resulting in accelerated PMF activation, a
loss that can be thought of as an accelerated version of ovarian ageing.
Indirect loss of PMFs as a result of accelerated activation could be
due to a loss of inhibitory factors from growing follicles that have
undergone atresia (Kalich-Philosoph et al., 2013; Roness et al., 2013).
It is important to bear in mind that chemotherapy drugs can also have
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damaging effects on the ovarian stroma and vasculature (Oktem and
Oktay, 2007; Meirow et al., 2007), either of which can, in turn, impact
negatively on the health of the follicular reserve, as well as impairing
normal follicle development.
Together, these considerations of both direct and indirect effects
on follicle pools at different stages of development provide a basis for
interpretation of the effects of chemotherapy and thus approaches
towards prevention of these adverse effects. Few such studies have
examined effects on human ovary, with most using rodent models.
As such, there is a pressing need for the effectiveness and safety of
the most promising potential protectants to be determined in the
human, a crucial step towards any subsequent clinical development.
This will require studies to ensure that the protectants do not interfere
with the efficacy of the cancer treatment and that they do not impair
the developmental competence of oocytes or lead to the survival
of oocytes with DNA damage in the form of genetic or epigenetic
mutations (Clarke and Vieux, 2015; Kirsch-Volders et al., 2019).
Ovarian damage from
chemotherapy and its potential
protection
The effects of chemotherapy treatment on future fertility are relevant
for both childhood cancers and those that affect women up to
the age of menopause. The most common childhood cancers are
leukaemia (around 26% of all registered cases), followed by central
nervous system tumours and lymphomas. In youngwomen, carcinomas
(around 30% of cases), followed by lymphomas, melanomas and
central nervous system tumours are most frequent, while in older
pre-menopausal women, the relevant diseases are breast cancer
(over 40% of cases), followed by melanoma, cervix and central
nervous system tumours (https://seer.cancer.gov/statistics/; https://
www.cancerresearchuk.org/health-professional/cancer-statistics/
incidence/ageheading-Two; Cronin et al., 2018). Chemotherapy drugs
are also used in the treatment of a wide range of non-malignant
diseases, including auto-immune illnesses, with chemotherapy con-
ditioning prior to stem cell transplant being increasingly used for
haematological conditions, such as sickle cell anaemia.
With such an extensive group of diseases, treatment can involve
administration of a wide range of chemotherapeutic classes and drugs,
including alkylating agents (CPM, busulphan and others); alkylating-like
platinum complexes (such as cisplatin [CIS]; anthracyclanes (including
doxorubicin [DOX]); taxanes (docetaxel and others); topoisomerase
inhibitors (such as etoposide); and vinca alkaloids (including vincristine).
The effects of chemotherapy drugs on female reproduction began to
be reported in the 1970s, initially associated primarily with CPM treat-
ment (see, for example, Miller et al., 1971; Fries et al., 1973; Koyama
et al., 1977), with reports of amenorrhea, ovarian suppression and
follicle destruction. From early in the development of chemotherapy
drug use, administration of one drug alone became rare, with patients
instead being treated with drug combinations. Given this, it has become
increasingly difficult to determine which particular drug is responsible
for the fertility-damaging effects, with relatively little known about the
ovarian toxicity of some drugs. Nonetheless, there is strong clinical
evidence that ovarian damage is particularly severe after administration
of alkylating and alkylating-like agents (Chow et al., 2016; van Dorp
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et al., 2018; Meirow and Nugent, 2001), while DOX, which is used
to treat a wide range of cancers, is amongst the non-alkylating agents
most closely linked to female reproductive problems (Bar et al., 2003;
Green et al., 2009; Bedoschi et al., 2016; Bedoschi et al., 2019). Conse-
quently, many of the chemicals currently being investigated as potential
protectants have been specifically tested to ameliorate damage induced
by CPM, CIS or DOX. As such, the mechanism of action of, and
potential protection against damage by, each of these three drugs are
examined in detail below. It should be borne in mind that other drugs
also have moderate or strong ovarian toxicity, particularly the alkylating
agent busulphan (Chow et al., 2016). Some potential protectants,
such as AMH, should, in theory, be effective against a wide range of
chemotherapy drugs and are discussed separately.
Cyclophosphamide
Action of cyclophosphamide (CPM) and main uses in treatment
CPM is an alkylating agent, capable of covalently binding alkyl groups
to DNA. Alkylating agents, originally derived from the mustard gas
chemical warfare agents, were the first drugs shown to result in tumour
regression. CPM itself is a pro-drug, metabolised by cytochrome P450
in the liver to form 4-hydroxycyclophosphamide, which is in turn
converted to phosphoramide mustard and acrolein. Phosphoramide
mustard is the primary active metabolite (Plowchalk and Mattison,
1991;Madden and Keating, 2014), inducingDNA crosslinking that leads
to the formation of adducts that prevent DNA replication. Phospho-
ramide mustard also affects mitochondria, leading to a reduction in
transmembrane potential and cytosolic cytochrome c accumulation.
CPM is used in the treatment of a wide range of cancers, particularly
the more frequent childhood cancers, melanomas and breast cancer,
including the treatment of pregnant cancer patients (Hahn et al., 2006).
It is also used in the treatment of auto-immune diseases, such as
systemic lupus erythematosis and rheumatoid arthritis.
Effect of CPM on the ovary
Human ovary studies. CPM was the first chemotherapy drug to be
linked to amenorrhea/POI and ovarian dysfunction (Miller et al.,
1971; Fries et al., 1973; Koyama et al., 1977), and it continues to
be regarded as one of the most gonadotoxic agents (Overbeek et al.,
2017; Chemaitilly et al., 2017). Nevertheless, there are only a limited
number of studies that have examined the effect of CPM on human
ovarian tissue. From these, it is difficult to determine the precise effects
of CPM on PMFs: while the PMF population has been shown to be
reduced in size following CPM-exposure (Meng et al., 2014), there are
reports both of direct damage to this follicle population (Li et al., 2014)
and of a reduction in PMF numbers following accelerated activation,
with the authors also suggesting that phosphoramide mustard itself
may even directly induce accelerated PMF activation (Kalich-Philosoph
et al., 2013; Lande et al., 2017). Direct effects have, however, been
clearly demonstrated on PMFs in the mouse (see below) and on
growing follicles in human ovarian tissue examined in vitro, with CPM
inducing increased granulosa cell apoptosis and follicular atresia (Asadi
Azarbaijani et al., 2015; Yuksel et al., 2015).
Non-human ovary studies. As with the clinical work, CPM was the
first drug shown to induce ovarian damage and follicle loss in the
mouse (Miller and Cole, 1970), and CPM exposure is regularly used
as a pre-treatment to induce widespread follicular atresia in a variety
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of experiments where the research examines the physiology of an
ovary devoid of follicles (see, for example, Goldman et al., 2017;
Kano et al., 2017; Melekoglu et al., 2018; Tsuyoshi et al., 2015). For
growing follicles, there is now a large body of evidence linking CPM
exposure to follicle atresia and granulosa cell apoptosis (Jarrell et al.,
1991; Ezoe et al., 2014; Piasecka-Srader et al., 2015; Yuksel et al., 2015;
Chen et al., 2016). Exposure of growing follicles to CPM, particularly
at earlier stages, has also been linked to embryo abnormalities and
to malformation in the next generation in later pregnancies (Barekati
et al., 2008; Meirow et al., 2001, respectively). The PMF pool is clearly
affected by CPM exposure (Meirow et al., 1999; Kalich-Philosoph et al.,
2013; Saleh et al., 2015; Chen et al., 2016; Goldman et al., 2017;
Pascuali et al., 2018; Nguyen et al., 2018; Luan et al., 2019), although
as with studies in the human ovary, it is not always clear whether PMF
loss is due to direct damage and/or a result of indirect loss due to
accelerated activation. Inflammation and vasculature damage have also
been reported (Ezoe et al., 2014; Saleh et al., 2015; Luo et al., 2017;
Pascuali et al., 2018). With CPM also administered to pregnant cancer
patients, the effects of CPM on the developing ovary has also been
investigated, with formation of fewer follicles formed (Fig. 1A) and
acceleration of PMF activation (Ray and Potu, 2010; Comish et al.,
2014). One recent study has demonstrated that maternal CPM expo-
sure prior to conception can affect the competence of the offspring’s
oocytes, which was associated with altered methylation of three
imprinted genes (H19, Igf2r and Peg3) (Di Emidio et al., 2019).
Molecular pathways of CPM-induced ovarian damage
Most of our understanding of precisely how CPM induces ovarian
damage has come from studies trying to prevent that damage (Table 1).
As expected, given what is known about its action on cancer cells,
there is clear evidence that CPM leads to an upregulation in apoptosis
in the ovary, as is evident from the rapid induction of DNA breaks
(Piasecka-Srader et al., 2015) and from a change in the expression
levels of pro- and anti-apoptotic genes (Petrillo et al., 2011; Pascuali
et al., 2018; Luan et al., 2019). Recent studies have demonstrated that
the DNA damage-induced pro-apoptotic protein PUMA plays a key
role in inducing oocyte apoptosis in rodents following CPM treatment
(Nguyen et al., 2018), as is also the case following irradiation (Kerr
et al., 2012). A decrease in production of antioxidant enzymes, such as
superoxide dismutase, has also been shown (Khedr, 2015; Melekoglu
et al., 2018). Work has also examined whether CPM stimulates the
mTOR/PTEN/Akt pathway, resulting in accelerated PMF activation.
Kalich-Philosoph et al. (2013) have shown induction of Akt, mTOR and
FOXO3a within 24 h of CPM exposure. Increased phosphorylation of
Akt and other parts in the pathway have also been shown by Goldman
et al. (2017), although in that instance, the tissue was examined
7 days after the end of treatment. One study has now demonstrated
that CPM specifically induces apoptosis in the oocytes of primordial
follicles, while also not finding increased activation of such follicles
(Luan et al., 2019). An inflammation response has been shown through
increased levels of the pro-inflammatory cytokines IL-6 and -8 and
TNFα alongside reduced levels of the anti-inflammatory IL-10, although
this was in response to administration of both CPM and busulfan (Luo
et al., 2017). CPM also leads, in mouse oocytes, to an increase in the
expression of the cell redox state sensor SIRT1, as the result of the
adaptive response to oxidative stress (Di Emidio et al., 2017). In fact,
SIRT1 is involved in both inflammation and oxidative stress, by inhibiting
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NF-kB signalling and stimulating the expression of antioxidants through
FoxO transcription factors, respectively (Xie et al., 2013; Salminen
et al., 2013).
Agents used to protect ovaries from CPM-induced damage
Potential protectants from CPM-induced damage have been investi-
gated to determine protection against direct loss of PMFs, accelerated
activation of PMFs, increased atresia of growing follicles and damage to
the ovarian vasculature (Fig. 1B, Table II). At present, only Sphingosine-
1-phosphate (S1P) and tamoxifen have been examined in the human
ovary (see below).
S1P and Ceramide 1 phosphate. Bioactive sphingolipids, S1P and
ceramide 1 phosphate (C1P), produced through ceramidemetabolism,
are inhibitors of the ceramide-induced death pathway and regulate
angiogenesis, vascular stability and permeability in a variety of tissues,
in both physiological and pathological conditions (Bonnaud et al., 2007;
Cuvillier et al., 1996). S1P prevents CPM-induced apoptotic follicle
death in both human ovarian xenografts (Li et al., 2014; Meng et al.,
2014) and isolated granulosa cells obtained from assisted reproduction
techniques (Li et al., 2017). Intrabursal C1P administration ameliorates
ovarian follicular and vascular development and restores fertility in
CPM-treated mice, with reduced TUNEL staining and decreased
cleaved caspase 3 and BAX expression, together clearly indicating
a reduction in apoptosis in all follicles analysed (Pascuali et al., 2018).
AS101. The immunomodulator AS101 is a non-toxic, tellurium-
based compound that modulates the PI3K/PTEN/Akt pathway,
reducing the Akt and rpS6 phosphorylation that is induced by CPM
(Makarovsky et al., 2003). It is used in clinical trials for neovascular
age-related macular degeneration due to its immunomodulating
characteristics and in the treatment of chemotherapy-induced
thrombocytopenia and psoriasis. In vivo treatment of mice with AS101
lowers CPM-induced loss of PMFs, as well as apoptosis of granulosa
cells in growing follicles, leading to improved reproductive outcomes
(Kalich-Philosoph et al., 2013). Mice born to dams whose fertility is
protected by AS101 treatment show no abnormalities, indicating that
the quality of the rescued oocytes is also protected. Importantly, it has
been demonstrated that not only does AS101 not interfere with the
primary anti-neoplastic activity of CPM in vivo, but, in fact, it also may
improve the efficiency of the anti-cancer activity of CPM, possibly due
to reduced inflammation (Roness et al., 2016; Kalich-Philosoph et al.,
2013; Kalechman et al., 1991; Roness et al., 2014).
Crocetin. Crocetin is a diapocarotenedioic acid, the main bioactive
compound in saffron, which protects primordial and growing follicles
from CPM-induced injury. Crocetin can also provide protection against
toxicant-induced oxidative stress along with underlying disorders in
numerous organs, tissues and cells (Xi et al., 2007). Crocetin admin-
istration (as with AS101) prevents an increase in SIRT1 expression,
suggesting that preservation of the redox balance can help the ovary
counteract CPM-induced ovarian damage (Di Emidio et al., 2017).
Despite this, crocetin and AS101 were not able to fully counteract
effects on oocyte imprinting in offspring (Di Emidio et al., 2019).
mTORC inhibitors. mTOR is a serine/threonine kinase and ametabolic
sensor that regulates cell growth, proliferation, autophagy and survival
(Wullschleger et al., 2006). Deletion of components of the mTOR
pathway, including PTEN- and TSC1-negative regulators, can induce
accelerated PMF activation in mice (Reddy et al., 2008; Adhikari
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et al., 2010; Chen et al., 2015). As such, in animal models, mTOR
stimulators accelerate activation of PMFs, while mTOR inhibitors
block the PMF-to-primary follicle transition (Sun et al., 2015). To
determine if inhibition of the mTOR pathway could be used as a
pharmacologic approach to prevent chemotherapy drug-induced POI,
CPM-treated mice were administrated one of two mTOR complex
(mTORC) inhibitors, either the clinically approved drug everolimus
(RAD001) that inhibits mTORC1 or the experimental drug INK128
that inhibits mTORC1 and 2. Both treatments preserved the ovarian
reserve, with ovaries containing PMF numbers that were comparable
to those in control mice; furthermore, fertility was restored (Goldman
et al., 2017). Similar results were obtained with the use of another
inhibitor of mTORC1, rapamycin (Zhou et al., 2017; Adhikari et al.,
2013).
Tamoxifen. The estrogen receptor modulator tamoxifen is widely
used in the treatment of estrogen receptor-positive breast cancers
and has been tested as an ovarian protectant against chemotherapy-
induced damage. In cultured neonatal rat ovaries, tamoxifen treat-
ment decreasedCPM-induced follicle loss, probably through decreased
expression of multiple genes related to inflammation, as well as tissue
remodelling and vasodilation (Piasecka-Srader et al., 2015). Further-
more, tamoxifen was able to prevent CPM-induced toxicity in PMFs
in vivo, protecting the fertility of treated rats (Ting and Petroff, 2010).
However, when tamoxifen was given in a randomised-controlled trial
to women treated with CPM, methotrexate and 5-fluorouracil, no
effect was observed on their ovarian function (Sverrisdottir et al., 2011;
Sverrisdottir et al., 2009).
Tyrosine kinase inhibitors. The use of inhibitors for the ATR-CHK2-
p63 apoptotic pathway was effective in vitro in protecting primordial
follicles from CPM-induced death (Luan et al., 2019).
Cisplatin
Action of CIS and main uses in treatment
CIS is a member of the platinum-based family of compounds. The
ability of CIS to inhibit cell division was first identified in the 1960s, and
it became the first FDA-approved platinum compound for cancer treat-
ment in 1978 (Kelland, 2007). It is of heavy metal composition and acts
as a DNA cross-linking agent that interferes with DNA repair mecha-
nisms, blocks cell division, elicits DNA damage and triggers apoptotic
cell death (Dasari and Tchounwou, 2014). The toxicity of CIS is partic-
ularly evident in tissues with a rapid cell turnover (Ozcelik et al., 2010).
CIS interacts with several different cellular components, but DNA is
its primary biological target (Roberts and Pera Jr, 1983). It exerts its
cytotoxic mode of action through binding to DNA, by preferentially
binding to N-7 positions of guanine and adenine to produce inter-
and intra-strand DNA adducts (Kalil and McGuire, 2002). The CIS-
induced DNA adducts are recognised by damage recognition proteins
which transduce the DNA damage signal downstream and modulate
several signal transduction pathways, such as Akt, c-ABL, ATR and
MAPK/JNK/ERK (Siddik, 2003;Wang and Lippard, 2005). CIS-induced
DNA damage activates cell cycle checkpoints, resulting in cell cycle
arrest (Siddik, 2003). Cell cycle checkpoints are necessary to allow the
cell repair mechanisms that enable the nucleotide excision repair com-
plex to remove DNA adducts and promote cell survival. When DNA
damage is minor, the DNA repair protein PARP detects the presence
of DNA strand breaks and activates their repair; if, however, DNA
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Table 1 Molecular pathways involved in chemotherapy-induced ovarian damage.
Molecular marker Drug Species Reference
.....................................................................................................................................................................................
Akt CPM Mouse Kalich-Philosoph et al. 2013; Goldman et al. 2017
CIS Mouse Chang et al. 2015; Jang et al. 2016; 2017
DOX Marmoset monkey Salih et al. 2015
ATM DOX Mouse Soleimani et al. 2011
Atr/CHEK1/CK1 CIS Mouse Kerr et al. 2012; Nguyen et al. 2018
Caspase activation CIS Human
Mouse
Bildik et al. 2015; Yuksel et al. 2015
Barberino et al. 2017
DOX Human
Marmoset monkey
Soleimani et al. 2011;
Salih et al. 2015
Mouse Xiao et al. 2017
DNA damage assessed by TUNEL CPM
CIS
DOX
Rat
Mouse
Mouse
Piasecka-Srader et al. 2015; Yeh et al. 2006
Barberino et al. 2017
Jang et al. 2017; Ben-Aharon et al. 2010;
Morgan et al. 2013; Roti Roti et al. 2014
DSBs CPM Rat Piasecka-Srader et al. 2015
DOX Marmoset monkey Mouse Salih et al. 2015; Soleimani et al. 2011;
Roti Roti et al. 2012, 2014; Xiao et al. 2017
Foxo3a CPM Mouse Kalich-Philosoph et al. 2013
CIS Mouse Chang et al. 2015; Jang et al. 2016; 2017
Glutathione CIS Rat
Mouse
Li et al. 2013
Barberino et al. 2017
GSK3 CIS Mouse Chang et al. 2015; Jang et al. 2016; 2017
γH2AX CIS Mouse Gonfloni et al. 2009; Rossi et al. 2017
DOX Marmoset monkey Mouse Salih et al. 2015; Soleimani et al. 2011;
Roti Roti et al. 2012, 2014; Xiao et al. 2017
MAPK, ERK CIS Human Mouse Damia et al. 2001; Chang et al. 2015;
Jang et al. 2016; 2017
MMP DOX Mouse Bar-Joseph et al. 2010; Zhang et al. 2017
mTOR CPM Mouse Kalich-Philosoph et al. 2013
NOXA & PUMA CPM
CIS
Mouse
Mouse
Nguyen et al. 2018
Kerr et al. 2012
PARP CIS Mouse Morgan et al. 2013; Chang et al. 2015
DOX Mouse Morgan et al. 2013; Bar-Joseph et al. 2010
Phosphorylation of PTEN CIS Mouse Chang et al. 2015; Jang et al. 2016; 2017
Pro-apoptotic, anti apoptotic genes
(Bax, Bcl-2, p53)
CPM
CIS
DOX
Mouse
Human
Mouse
Petrillo, et al. 2011
Pascuali et al. 2018
Damia et al. 2001
Zhang et al. 2017
Pro-inflammatory cytokines
(IL-6, IL-8, TNFα)
CPM Mouse Luo et al. 2017
Reactive oxygen species CIS
DOX
Rat
Mouse
Ozcan et al. 2015
Bar-Joseph et al. 2010; Zhang et al. 2017
SIRT1 CPM Xie et al. 2013; Di Emidio et al. 2017
StAR, P450scc DOX Mouse Zhang et al. 2017
Superoxide dismutase reduction CPM
CIS
DOX
Rat
Rat
Mouse
Mouse
Khedr 2015
Melekoglu et al. 2018
Li et al. 2013
Barberino et al. 2017; Bar-Joseph et al. 2010;
Zhang et al. 2017
Tap63 CIS Mouse Gonfloni et al. 2009; Kim et al. 2018;
Tuppi et al. 2018
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damage is extensive and DNA repair is not completed, PARP activation
can initiate cell death through apoptosis or necrosis (Soldani and
Scovassi, 2002). In addition to binding covalently to DNA, CIS can also
bind to nuclear and cytoplasmic proteins which can cause adverse toxic
effects in patients (Kalil and McGuire, 2002; Chovanec et al., 2017), and
it is possible that these mechanisms may add to its gonadotoxicity.
Effect of CIS on the ovary
Human ovary studies. There are limited clinical data available on the
ovarian toxicity of CIS. Female patients treated with CIS have usually
received it as part of a multiple-drug regimen, making it difficult to
elucidate exact mechanisms of CIS-induced ovarian toxicity. CIS is
generally considered to have moderate ovarian toxicity, although, to
the best of our knowledge, only one clinical study has reported this,
finding mild to moderate rates of amenorrhea and an increased risk
of ovarian failure and infertility following treatment with a multi-drug
regimen that included CIS (Maneschi et al., 1994). Others have found
no detrimental effects on fertility following CIS treatment, particularly
for germ cell tumours (Brewer et al., 1999; Weinberg et al., 2011),
although effects on male fertility are clear (Chow et al., 2016). CIS-
induced damage has been found in studies that have cultured human
ovarian cortical pieces or granulosa cells in its presence, resulting in a
decrease in follicle numbers and a reduction in steroidogenic activity
(Bildik et al., 2015; Yuksel et al., 2015).
Non-human ovary studies. Most of the information on the ovarian
toxicity of CIS has been derived from animal studies. There is a
growing body of evidence demonstrating a loss of ovarian reserve
and increased follicular atresia following CIS exposure in mouse and
rat ovaries (Gonfloni et al., 2009; Yuksel et al., 2015; Kim et al., 2013;
Morgan et al., 2013; Rossi et al., 2017; Nguyen et al., 2018), with imma-
ture oocytes being particularly susceptible (Rossi et al., 2017; Morgan
et al., 2013). Studies examining effects of CIS exposure on follicles
frequently report the loss of PMFs, through PMF death directly and/or
indirectly due to accelerated activation; in either case, this would
ultimately lead to POI (Yucebilgin et al., 2004; Chang et al., 2015). If CIS
targets growing follicles, their death will result in decreased secretion of
factors, such as AMH, that can inhibit PMF activation, and CIS has been
shown to reduce circulating AMH and inhibin-α levels, corresponding
with a decrease in the percentage of AMH-positive follicles (Yeh et al.,
2006; Li et al., 2014; Ozcan et al., 2015; Yeh et al., 2008).
Molecular pathways of CIS-induced ovarian damage
Despite the therapeutic potential of CIS being discovered over 40 years
ago, its mechanisms of action are still not fully understood. The
proposed pathways to damage include CIS eliciting DNA damage that
leads to the activation of apoptotic pathways through the p53 family of
signalling and damage through oxidative stress and production of free
radicals (Table 1). Exposure to CIS increases DNA damage in ovarian
cells, resulting in apoptosis, as is evident from increased DNA damage,
TUNEL and activation of apoptotic genes, such as caspase 3 (Bildik
et al., 2015; Yuksel et al., 2015; Barberino et al., 2017; Jang et al.,
2017). The tumour-suppressor p53 protein and members of its family
play a crucial role in the degree to which CIS-induced DNA damage
is repaired, ultimately determining cell fate. ATR, a kinase involved in
checkpoint activation, is activated by CIS, and in turn can activate p53,
as well as specific pathways of the MAPK cascade (Damia et al., 2001).
The p53 homologue p63, specifically its isoform TAp63α, is expressed
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in dormant and growing oocytes (Suh et al., 2006). This protein is a key
mediator of the DNA damage response within the ovary. CIS activates
TAp63α thorough an ATR/CHEK1/CK1 pathway (Tuppi et al., 2018;
Kim et al., 2018); this increases the expression of PUMA and NOXA,
leading to apoptosis of those oocytes that are irreparably injured fol-
lowing CIS treatment, directly inducing follicle death (Kerr et al., 2012;
Nguyen et al., 2018). CIS-exposure also leads to increased reactive
oxygen species and a decrease in the ovarian antioxidant capacity
(Ozcan et al., 2015). This has been correlated with decreased activities
of the antioxidant enzyme superoxide dismutase (Bansod et al., 2017)
and the thiol anti-oxidant glutathione (GSH) following CIS exposure
(Li et al., 2013; Barberino et al., 2017). Exposure to CIS results in
increased phosphorylation of key proteins in the PTEN/Akt/FOXO3a
pathway, including PTEN, Akt, GSK3, FOXO3a and ERK, leading to
nuclear export of FOXO3a which in turn suppresses its transcription
activities, together leading to accelerated activation of PMFs (Jang et al.,
2016; Chang et al., 2015).
Agents used to protect ovaries from CIS-induced damage
There is now a range of agents aiming to protect the ovary against
CIS-induced damage, preventing direct loss of PMFs, accelerated PMF
activation or follicular atresia (Fig. 1B, Table II). However, there are
no published data on the potential of any of these to protect against
damage in the human ovary.
Tyrosine kinase inhibitors. The p53 family member TAp63α is respon-
sible for DNA damage-induced apoptosis of oocytes within PMFs.
TAp63α is the only isoform of TAp63 expressed by the oocyte and
becomes activated after DNA damage; tyrosine kinase signalling is
involved in this key regulatory pathway (Suh et al., 2006). Recently,
CHK2 and the executioner kinase CK1 have been identified as impor-
tant for the elimination of mouse oocytes following double-stranded
breaks in DNA (Bolcun-Filas et al., 2014; Tuppi et al., 2018), and their
function is essential for downstream activation of TAp63 (Kehrloesser
et al., 2018). In vitro, pharmacological inhibition of CHK2/CK1 was
shown to be effective at rescuing oocytes from TAp63-mediated apop-
tosis induced by CIS or by DOX (see below) or following γ -irradiation
(Rinaldi et al., 2017; Tuppi et al., 2018). The same results have been
obtained using inhibitors of ATM and ATR (Tuppi et al., 2018; Kim et al.,
2018), indicating that the TAp63 pathway could be an effective target
for developing protective strategies in oncofertility. Pharmacological
inhibitors of ATM, ATR, CHK2 and CK1 are already being used in
preclinical and clinical trials (Rundle et al., 2017), potentially expediting
their application to this field, while inhibitors of the downstream targets
of TAp63α, NOXA or PUMA still need to be discovered.
Imatinib is an inhibitor of the oncogenic BCR-Abl tyrosine kinase
enzyme and is itself used in the treatment of cancers, such as chronic
myeloid leukaemia and gastro-intestinal stromal tumours. Data on
the efficacy of imatinib against damage by CIS have been conflicting,
with some studies finding protective effects (Gonfloni et al., 2009;
Maiani et al., 2012; Kim et al., 2013), and others finding either no
evidence of protection or even deleterious effects (Kerr et al., 2012;
Zamah et al., 2011). All published studies have been carried out using
the mouse as a model, and there are no data on effects on the
human ovary. Recent work examining the mechanism of activation of
TAp63α has demonstrated that imatinib is able to protect oocytes from
CIS-induced death without interfering with TAp63α tetramerization
(Tuppi et al., 2018). The same conclusion was reached in another study
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Table II Agents used to protect ovaries from chemotherapy-induced damage.
Protectant Drug Target action Species Reference
.....................................................................................................................................................................................
AMH/MIS CPM Accelerated PMF
activation
Mouse Kano et al. 2016
DOX Sonigo et a.l 2018
Carboplatin
ATM inhibitors: CIS Direct loss of PMFs Mouse Tuppi et al. 2018
ETP-46464 DOX Kim et al. 2018
KU55399
ATR inhibitors: CIS Direct loss of PMFs Mouse Kim et al. 2018
ETP-46464 DOX Luan et al. 2019
AZD6738 CPM
AS101 CPM Accelerated PMF activation Mouse Kalich-Philosoph et al. 2013
Di Emidio et al. 2017
Bortezomib DOX Atresia Mouse Roti Roti et al. 2014
Ceramide-1-phosphate CPM Direct loss of PMFs Mouse Pascuali et al. 2018
Atresia
Vascularization
CHK2 inhibitors: CIS Direct loss of PMFs Mouse Rinaldi et al. 2017
BML277 DOX Tuppi et al. 2018
LY2603618 CPM Luan et al. 2019
LY2606368
CK1 inhibitors: CIS Direct loss of PMFs Mouse Tuppi et al. 2018
MK-8776 DOX
CHIR-124
PMF670462
PMF4800567
PMF5006739
Crocetin CPM Accelerated PMF activation Mouse Di Emidio et al. 2017
Dexrazoxane DOX Atresia Mouse Kropp et al. 2015
Ghrelin CIS Accelerated PMF activation Mouse Jang et al. 2017
G-CSF CIS Atresia Mouse Skaznik-Wikiel et al. 2013
Vascularisation Akdemir et al. 2014
Imatinib CIS Direct loss of PMFs Mouse Kim et. 2013
Atresia Maiani et al. 2012
Zamah et al. 2011
Rinaldi et al. 2017
Tuppi et al. 2018
Gonfloni et al. 2009
Kim et al. 2018
Luteinizing Hormone CIS Direct loss of PMFs Mouse Rossi et al. 2017
Atresia Tuppi et al. 2018
MDR1 CPM Delivery to ovary Mouse Brayboy et al. 2013; 2017
Salih 2011
Wang et al. 2018
Melatonin CIS Accelerated PMF activation Mouse Jang et al. 2016
Mesna CIS Atresia Rat Li et al. 2013
Mirtazapine CIS Atresia Rat Altuner et al. 2013
mTORC inhibitors: CPM Accelerated PMF activation Mouse Adhikari et al. 2013
(Continued)
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Table II Continued
Protectant Drug Target action Species Reference
.....................................................................................................................................................................................
Everolimus (RAD001) CIS Goldamn et al. 2017
INK128 Zhou et al. 2017
Rapamycin Tanaka et al. 2018
Resveratrol CIS Atresia Rat Ozcan et al. 2015
Sphingosine-1- phospate CPM Direct loss of PMFs Mouse Morita et al.2000
Rat Li et al. 2017
Human Li et al. 2014
Meng et al. 2014
Sildenafil Citrate CIS Atresia Rat Taskin et al. 2015
Tamoxifen CPM Direct loss of PMFs Rat Ting and Petroff 2010
Inflammation Human Piasecka-Srader et al. 2015
Sverrisdottir et al. 2009
Sverrisdottir et al. 2011
which generated a conditional knockout mouse with an oocyte-specific
deletion of Abl1 and Abl2; ovaries from these mice treated with CIS
show no protection against apoptosis (Kim et al., 2018). Imatinib is
not an inhibitor of a specific tyrosine kinase signalling pathway, but can
affect a range of pathways, including those downstream of c-Kit, the
PDGF receptor and, to a lesser extent, c-Src (Seeliger et al., 2007). As
tyrosine kinase signalling is involved in several key regulatory processes
in the ovary, it could be that the mixed reports about the action of
imatinib results from both beneficial and detrimental effects on the
ovary due to its range of actions, and that inhibiting specific tyrosine
kinase signalling pathways could provide the ovary with more effective
protection.
Luteinizing Hormone. In addition to its cardinal roles in ovulation and
induction and maintenance of the corpus luteum and its use in fertility
programs for assisted reproduction techniques, recent research has
shown that luteinizing hormone (LH) is also able to protect PMFs
from the deleterious effects of CIS in prepubertal mice (Rossi et al.,
2017). When CIS is administered concomitantly with LH, there is little
degeneration of PMFs and mice maintain their fertility. LH is able to
stimulate the DNA repair mechanisms and at the same time block
CIS-induced apoptotic pathways in oocytes, an effect shown to be
indirect, since the oocyte lacks LH receptors. LH does not counteract
the activation/tetramerization of TAp63α (Rossi et al., 2017; Tuppi
et al., 2018); its mechanism of action remains to be elucidated.
Melatonin and ghrelin. Melatonin (N-acetyl-5-methoxytryptamine)
is a hormone synthesised and secreted mainly by the pineal gland
(Venegas et al., 2012; Reiter et al., 2013; Reiter et al., 2014). Apart
from its use in sleep disorders, melatonin can also reduce the side
effects of anticancer drugs by removing hydrogen peroxide, singlet
oxygen, superoxide anion radicals and peroxyl radicals (Casado-Zapico
et al., 2010; Pariente et al., 2016). Its potential protective effect was
first investigated in the male; in mouse testis, melatonin prevents
CIS-induced testicular toxicity by scavenging free-radical products
(Atessahin et al., 2006). More recently, protection has also been found
in the female, where co-administration of CIS and melatonin has been
shown to lead to a reduction in TUNEL in granulosa cells, resulting in
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reduced atresia of growing follicles and suppression of phosphorylation
of the PTEN/AKT/FOXO3a pathway, thus limiting PMF activation
(Jang et al., 2016).
Ghrelin is a hormonal peptide produced by cells in the gastrointesti-
nal tract. Although it is known as the “hunger hormone,” increasing evi-
dence supports a more complex role in the regulation of metabolism.
As with melatonin, ghrelin has protective activity against CIS-induced
testicular damage (Garcia et al., 2015;Whirledge et al., 2015). Oocytes
within PMFs express receptors for both ghrelin and melatonin, and the
combination has been tested for activity against CIS-induced damage
(Jang et al., 2017). Co-administration of the two hormones blocks
PMF loss by reducing PTEN and FOXO3a phosphorylation. Given the
presence of their receptors in the oocyte, it is possible that these
hormones have a direct action on PMFs, potentially affecting their
capacity to remain in a quiescent state.
Antioxidants. Four different antioxidants, mesna, mirtazapine, resver-
atrol and sildenafil citrate, have been tested for their protective effects
on the ovarian reserve of rats treated with CIS (Li et al., 2013; Ozcan
et al., 2015; Taskin et al., 2015; Altuner et al., 2013). Mesna, sildenafil
citrate and resveratrol prevented the loss of AMH-positive follicles;
mirtazapine also improved fertility. The antioxidative enzymatic activity
of superoxide dismutase and glutathione were increased after co-
administration of mesna ormirtazapine with CIS. These results indicate
that the maintenance of low levels of free radicals in the ovary is
important to promote the survival of the ovarian reserve.
mTORC inhibitors. Everolimus prevents the loss of primordial follicle
in cisplatin chemotherapy-induced treated mice, in which the activation
of the PI3K/PTEN/AKT pathway was detected (Chang et al., 2015;
Tanaka et al., 2018).
Doxorubicin
Action of DOX and main uses in treatment
The anthracycline antibiotic DOX (14-hydroxydaunomicyn) is a com-
monly used chemotherapy agent often known by its main trade names,
Adriamycin or Rubex. It was originally isolated from Streptomyces
peucetius in the 1970s and is now used to treat a large range of cancers,
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including breast, lung, gastric, ovarian, bladder, thyroid, leukaemia,
sarcoma, lymphoma, neuroblastoma, Wilms’ tumours and paediatric
cancers (Blum and Carter, 1974; Roti Roti et al., 2014; Xiao et al.,
2017). The main and most widely recognised mechanism of DOX is
the inhibition of the nuclear enzyme topoisomerase II. Topoisomerase
II prevents supercoiling and twisting of the DNA during replication
by producing double-strand nick and resealing of the cleaved DNA
and is, therefore, particularly abundant in the G2/M cell cycle phase
transition. DOX prevents topoisomerase II-DNA complex formation
after the nicking phase, with an accumulation of DNA fragments
which ultimately induces cell death. In addition, DOX stimulates the
production of oxygen-free radicals and other reactive oxygen species
(Tokarska-Schlattner et al., 2006) and is responsible for mitochondrial
dysfunction (Clementi et al., 2003). Both free radical production and
mitochondrial damage have a negative impact on cellular metabolism
and membrane integrity, resulting in severe side effects. DOX also
intercalates into DNA, impairing DNA replication and RNA and
protein synthesis (Kiyomiya et al., 1998; Thorn et al., 2011; Paik et al.,
1998; Zhang et al., 2017).
Effect of DOX on the ovary
Human ovary studies. Amongst other off-target effects, infertility has
been reported in both adult and childhood patients as a consequence
of regimens that include the use of DOX (Lipshultz et al., 2017). The
probability of amenorrhea following treatments that includes the use
of DOX ranges from 7% to 80%, primarily depending on the age
of the woman at the time of exposure (Ben-Aharon et al., 2010;
Letourneau et al., 2012; Knobf, 2006). However, as with many studies
that investigate the effect of chemotherapy on fertility by examining
time until menses resumption, these findings may not accurately reflect
the full degree of gonadotoxic damage or the total effect on fertility
lifespan, since full examination of either requires very long-term follow-
up studies. Moreover, as with CPM and CIS, it is difficult to clearly
isolate the role of a single drug, such as DOX when drugs are adminis-
tered in combination. Only two studies have investigated the direct
role of DOX on the human ovary (Li et al., 2014; Soleimani et al.,
2011), with both studies using human ovarian cortex examined either
in vitro and/or after xenotransplantation into immunocompromised
mice. This work has also highlighted DOX-induced damage to the
microvasculature as well as necrosis of the ovarian stromal tissue
(Soleimani et al., 2011).
Non-human ovary studies. DOX affects cortical blood vessels in
the mouse model, as well as in the human ovary, inducing fibrosis
(Ben-Aharon et al., 2010). DOX has been shown to cross the follicle
basement membrane and accumulate in the DNA and mitochondria
of the oocyte (Bar-Joseph et al., 2010). A dose-dependent depletion
of follicles, both primordial and early growing, has been found in many
studies (Morgan et al., 2013; Perez et al., 1997; Roti Roti and Salih, 2012;
Roti Roti et al., 2014; Aliotta et al., 2005; Tuppi et al., 2018). Later
stages of follicle development are also affected by DOX treatment,
resulting in a reduction in secondary and antral follicles. Furthermore,
DOX decreases the ovulation rate, and although the ovulated oocytes
appear morphologically normal, blastocyst number (Bar-Joseph et al.,
2010), litter size (Kropp et al., 2015), and pup birth weight (Roti Roti
et al., 2014) are reduced. The main DOX-induced damage in follicles
appears to be in the mitotically active granulosa cells, with damage to
oocytes being a consequence of follicle disruption (Bar-Joseph et al.,
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2010; Morgan et al., 2013; Roti Roti et al., 2012; Roti Roti et al., 2014;
Wang et al., 2018). Ultimately, DOX exposure causes a reduction in
fertile lifespan (Roti Roti et al., 2014).
Molecular pathways of DOX-induced ovarian damage
Apoptosis is the main, and certainly the most studied, process of cell
death triggered by DOX in the ovary, although the exact pathway
(s) is still somewhat unclear. Exploration of DOX-triggered apoptosis
has made possible identification of several markers of programmed
cell death in both human and animal model tissues (Table 1). PMFs
in DOX-treated human ovarian cortex show increased expression
of γH2AX and cleaved caspase 3 (Soleimani et al., 2011). Mouse
granulosa and stromal/thecal cells isolated from growing follicles, as
well as oocytes, have double-strand DNA breaks after DOX injection
(Roti Roti et al., 2014; Roti Roti et al., 2012; Xiao et al., 2017). Double-
strand breaks and γH2AX are also increased in antral follicles in
marmoset monkey ovary exposed to DOX (Salih et al., 2015), as are
metaphase II oocytes which undergo apoptosis after DOX exposure
in vitro (Perez et al., 1997; Soleimani et al., 2011). As downstream
effectors of the apoptotic pathway, the death regulating genes Bax
and Bcl-2 appeared to be involved (Zhang et al., 2017), with oocytes
collected from Bax-deficient animals resistant to DOX-induced apop-
tosis (Perez et al., 1997). As previously described, TAp63α becomes
activated after oocyte DNA damage, and DOX can act on the TAp63
pathway to directly induce PMF loss (Tuppi et al., 2018). Granulosa
cells exposed in vitro to DOX exhibit an increase in expression of p53
mRNA (Zhang et al., 2017), while the neonatal mouse ovary exhibits
an increase in the apoptotic marker PARP (Morgan et al., 2013).
As a late marker in the apoptotic pathway, TUNEL-positive cells are
increasedwhen the ovary is exposed toDOX (Ben-Aharon et al., 2010;
Morgan et al., 2013; Roti Roti et al., 2014). Other molecular pathways
have also been suggested to play a role in the gonadotoxicity caused
by DOX. Accumulation of reactive oxygen species and superoxides,
along with a decrease in mitochondrial membrane potential, have been
observed in DOX-treated granulosa cells, suggesting involvement of
oxidative stress mitochondrial-mediated apoptosis (Bar-Joseph et al.,
2010; Zhang et al., 2017). Only preliminary indications are available as
to whether the PI3K signalling pathway is activated byDOX,with AKT1
but not PTEN expression increased in marmoset ovary (Salih et al.,
2015).
Agents used to protect ovaries from DOX-induced damage
Protectants against ovarian damage by DOX resulting in reduced
activation of PMFs or follicular atresia have all been developed using
the mouse as a model (Fig. 1B, Table II). However, none of these have
been tested for their ability to protect against damage in the human
ovary.
Sphingosine-1-phosphate. Morita et al. (2000) reported the first use
of the sphingolipid S1P as a protector from oocyte apoptosis when
induced by exposure to 0.1 Gy of ionizing radiation. To confirm the
role of S1P, knockoutmice lacking the acid sphingomyelinase genewere
generated; in that mouse, germ cells were resistant to apoptosis and to
DOX-induced DNA damage. In the human ovary, S1P prevents DOX-
induced apoptotic follicle death in ovarian xenografts (Li et al., 2014;
Meng et al., 2014).
Dexrazoxane. The iron-chelating EDTA derivative dexrazoxane can
reduce DOX-induced DNA double-strand breaks, by chelating iron
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and inhibiting topoisomerase II. It is already used in cancer therapies,
protecting the heart and skin from other off-targets effects of DOX
without altering the effectiveness of DOX as a chemotherapeutic
drug (Reichardt et al., 2018; Langer, 2014). In vitro and in vivo co-
administration of DOX and dexrazoxane reduces ovarian DNA
double-strand breaks and granulosa cell death, with dexrazoxane
pre-treatment significantly restoring fertility in vivo (Kropp et al.,
2015).
Bortezomib. Proteasome inhibitors have been developed as anti-
cancer agents and several are either approved for clinical use to treat
melanomas and lung cancers or currently in trials (Kouroukis et al.,
2014). MG-132 and bortezomib both directly compete with DOX for
proteasome binding, thus preventing nuclear accumulation of DOX in
a leukemia cell line and also in cardiac cells (Amiri et al., 2004; Huang
et al., 2012; Pajonk et al., 2005). Female mice treated in vivo with
bortezomib show reduced DOX-induced DNA damage in all ovarian
cell types, resulting in reduced preantral follicle atresia. Fertility studies
have shown that bortezomib pretreatment leads to an increase in litter
size and pup weight following DOX treatment, thus improving post-
chemotherapy fertility (Roti Roti et al., 2014).
Tyrosine kinase inhibitors. Pharmacological inhibition of ATM, ATR,
CHK2 or CK1 are all effective in vitro at rescuing oocytes from DOX-
induced TAp63-mediated apoptosis (Rinaldi et al., 2017; Tuppi et al.,
2018), although imatinib was not found to confer protection against
DOX-induced damage to ovarian follicles (Morgan et al., 2013). The
kinetics of DOX action are reported to be faster than that of CIS,
probably because DOX directly induces double-strand breaks while
CIS creates DNA adducts (Tuppi et al., 2018).
Protective agents acting independently of
specific chemotherapy drug actions
Most of the research into potential protectants discussed above has
been designed with the aim of protecting the ovary against a spe-
cific chemotherapy drug or drug class. Other potential protectants
should, at least in theory, provide protection against a wide range of
chemotherapy drugs, either by blocking a common damage pathway
or by reducing the delivery of drugs to the ovary.
Protectants against specific damage pathways
Protection against increased PMF activation: AMH. AMH is primarily
produced by granulosa cells of developing follicles and can inhibit
activation of PMFs, at least in rodents. The situation in the human ovary
is less clear, with publications showing both initiation and suppression
of primordial follicle growth in response to AMH (Carlsson et al.,
2006; Schmidt et al., 2005). The hypothesis that accelerated activation
of PMFs, following the chemotherapy drug-induced death of growing
follicles, is an important pathway leading to depletion of the PMF pool
has led to the suggestion that AMH treatment might be an effective
protectant against a wide range of drugs. Two recent studies have
investigated this, examining the effectiveness of AMH at protecting
the mouse ovary from CPM- and DOX-induced damage, along with
damage from the platinum-containing agent carboplatin (Kano et al.,
2017; Sonigo et al., 2018).
Kano and colleagues showed a significant protective effect of AMH
administration from damage induced by each of CPM, DOX and
carboplatin, particularly in terms of protecting the PMF pool. AMH
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appeared most effective against DOX-induced damage, but it is difficult
to draw conclusions from this study about the comparative effective-
ness of AMH against the different drugs, since the doses that were
administered for each chemotherapy drug resulted in a lowering of
the PMF pool to a different extent in each case (Kano et al., 2017).
Nonetheless, this work highlights the importance of studying a range
of chemotherapy drugs in this research.
More recently, Sonigo et al. (2018) also found that AMH reduced
the loss of follicles induced by CPM, with protection against the
reduction in number of oocytes that could be recovered following
ovarian stimulation, although an effect on fertility was not shown.
That study also provided data suggesting that AMH regulates FOXO3a
phosphorylation and induces autophagy in ovaries. These results lead
the authors to discuss the hypothesis that AMH reduces PMF loss
induced by CPM through autophagy activation.
Both studies highlight the potential value of AMH as a protec-
tive agent in the field of oncofertility, with activity against several
chemotherapeutic drugs. Additionally, since it is thought to be only
involved in the regulation of reproductive function, it may not interfere
with the therapeutic effects of chemotherapy.
Protection of ovarian blood vessels: Granulocyte-colony stimulating factor.
Granulocyte-colony stimulating factor (G-CSF) is a cytokine that stim-
ulates hematopoietic progenitor cell growth and has been successfully
used alongside cancer therapy to overcome chemotherapy-induced
myelosuppression (Ciurea et al., 2019). G-CSF increases microvessel
density and decreases follicle loss in CPM- and busulfan-treated female
mice compared to control groups: moreover, G-CSF can partially
restore fertility (Skaznik-Wikiel et al., 2013). G-CSF, with or without
stem cell factor, also extends the time until the onset of POI in mice
treated with alkylating chemotherapy (Skaznik-Wikiel et al., 2013). An
effect has also been seen against CIS in the rat, where all follicle counts
(primordial, primary, secondary and tertiary) and serum AMH levels
were significantly increased in the G-CSF-CIS treated group compared
to the control group (Akdemir et al., 2014). Despite the clinical use
of G-CSF in cancer treatment, making it a good ovarian protectant
candidate to test clinically, there are no data on the effectiveness of
G-CSF at protecting the human ovary against damage by chemotherapy
drugs.
Protectants against chemotherapy drug delivery to the ovary
Upregulation of multidrug resistance gene 1. Multidrug resistance gene
1 (MDR1) is a phase three drug transporter enzyme involved in the
metabolism, elimination and detoxification of chemotherapy drugs.
By promoting the transport and efflux of various lipid-soluble anti-
cancer agents, upregulation of MDR1 has been linked with resistance
to chemotherapy (Fojo et al., 1987; Lepper et al., 2005). Retroviral
transduction has been used to upregulate MDR1 in a granulosa cell
line in order to reduce the uptake of chemotherapeutic agents into
these cells. This upregulation of MDR1 was reported to protect
granulosa cells from the toxic effects of both DOX and paclitaxel
in a dose-dependent manner, with the MDR1-transduced granulosa
cells showing significantly increased cell survival following treatment
with either drug (Salih, 2011). These results are supported by other
studies, where the inhibition of MDR transporters in human andmouse
oocytes, as well as deletion of the gene in mice, has led to increased
susceptibility to CPM toxicity (Brayboy et al., 2017; Wang et al., 2018;
Brayboy et al., 2013).
D
ow
nloaded from
 https://academ
ic.oup.com
/hum
upd/advance-article-abstract/doi/10.1093/hum
upd/dm
z027/5585503 by U
niversity of Edinburgh user on 23 O
ctober 2019
14 Spears et al.
Nanoparticles. A novel approach to ovarian protection, and indeed to
reduce other toxicities, has been to encapsulate the chemotherapeutic
drug arsenic trioxide inside nanoparticles that specifically target cancer
cells (Ahn et al., 2013), with the result being decreased plasma levels
and toxicity of these drugs. This strategy could be applied to other
chemotherapeutic agents, to target more specifically target the cancer
cells while protecting the gonads from damage.
Conclusion
The last decade has seen the development of a number of potential
methods for protecting the ovary against damage from chemother-
apy drugs (Fig. 1B, Table II). Such protectants are needed not only
to preserve fertility but also to allow females to retain endocrine
function and avoid the detrimental health consequences of POI. Most
of that work has been carried out using rodent models, primarily the
mouse. One strategy for such animal model studies, which has been
used infrequently to date, is to examine protectants in an animal that
has cancer (Qin et al., 2018), although this could be very effective.
Surprisingly, few studies to date have examined the effectiveness of
potential protectants directly in human ovarian tissue, although this
strategy has been used to investigate the potential of S1P and tamoxifen
to protect against CPM-induced damage. In the near future, it is vital
for more studies to determine the effect of these drugs in the human
ovary and/or for research to use large, monovulatory mammalian
species as models. With that work, the hope then is that some of
these protectants will be able to be taken into clinical trials. Clearly,
any protectant will need to not only shield the ovary from damage but
will also need to be shown not to interfere with the efficacy of the
chemotherapy treatment. In light of that, potential protectants that are
already administered to cancer patients are of particular interest here,
including AS101, imatinib and G-CSF.
Notwithstanding our improved understanding of female reproduc-
tion in recent years, we still do not know what determines whether
or not an individual PMF will undergo activation and initiate growth
at a particular time. A number of potential protectants under cur-
rent investigation involve manipulating the Akt pathway, stressing the
importance of greater understanding of its role, including in the human
ovary. The expression of p-Akt in mice pups is usually restricted to
stromal cells and often the evaluation of p-Akt is by Western blotting
on whole ovaries. Nevertheless, only recently, its co-expression in
primary oocytes upon exposure to CPM with the activated apoptotic
protein PARP was shown (Luan et al., 2019). We also have only a
limited understanding of what constitutes a healthy oocyte, and it is of
course vital that any clinically used protectant maintains the health and
developmental competence of the oocyte. Therefore, the implications
for the developmental competence of oocytes exposed to potential
protectants, as well as chemotherapy agents, should be explored,
taking into consideration the long reproductive lifespan of women,
and the background deterioration of oocyte “quality” and repair
mechanisms with age (Kujjo et al., 2011; Vandenbroucke et al., 2017;
Momen et al., 2017). CPM treatment in particular is well established to
result in abnormalities in rodent offspring following sub-sterilising dose
exposure, although there is no evidence of increased risk of abnormal-
ities or of genotoxicity in humans following maternal radiotherapy or
chemotherapy exposure (Signorello et al., 2012; Winther et al., 2009;
Winther et al., 2012; Vandenbroucke et al., 2017). Future studies will
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need to examine whether or not there is evidence of such effects
after administration of protectants, as well as of chemotherapeutics.
Epigenetic inheritance through the germ line or the potential for
transgenerational effects should also be considered in future studies
(Wei et al., 2015; Clarke and Vieux, 2015; Di Emidio et al., 2019). It is
notable that most protectants under investigation focus on protecting
against ovarian follicle death but it is also important to bear in mind
that the stromal environment contributes to the health of follicles,
and not focus research exclusively on direct effects on the follicles. At
present, protecting the ovary against stromal damage appears to have
had little attention (Fig. 1B), possibly one consequence of the majority
of research using rodents as models. Overall, however, recent years
have seen the development of many potential protectants, acting on
a wide range of different pathways and with evidence for efficacy in
the mouse model, offering hope for the subsequent development of
clinically effective treatment.
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